News & Events zu Leap Therapeutics Inc (LPTX)LPTXLeap Therapeutics Inc

Leap Therapeutics Rebrands as 'Cypherpunk Technologies,' Adopts 'CYPH' Ticker

Leap Therapeutics (LPTX) announced it will change its name to Cypherpunk Technologies and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50M of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (CYPH)as part of the rebranding under the Cypherpunk name. The company will begin trading under its new name and ticker symbol CYPH on Thursday, November 13. Until then, investors can continue to buy and sell the company's stock under the current ticker symbol LPTX without interruption. Cypherpunk also announced the appointment of Khing Oei and Will McEvoy to its Board of Directors, effective November 11, 2025. This strategic move comes as part of the company's recently completed $58.88M private placement led by Winklevoss Capital to initiate a digital asset treasury strategy. Notably, Winklevoss Capital was the only institutional investor in the private placement, contributing a majority of the total raised.

Leap Therapeutics announces findings from Phase 2 trial of sirexatamab

Leap Therapeutics announced final results from Part B of the DeFianCe study, a Phase 2 study of sirexatamab, an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy compared to bevacizumab and chemotherapy in patients with microsatellite stable, or MSS, colorectal cancer, or CRC, who have received one prior systemic therapy for advanced disease. The final clinical results were presented on behalf of the DeFianCe study investigators by Zev Wainberg, MD, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA in a Mini Oral session at the European Society for Medical Oncology Congress 2025 in Berlin, Germany. The DeFianCe study was a two part, open-label, multi-country study. Part A of the DeFianCe study enrolled 33 patients, including a significant number of patients who had early progression on first-line therapy, previous exposure to bevacizumab, tumors with RAS mutations, or liver and lung metastases. The study expanded into a 188 patient Part B randomized controlled trial. The primary objective of the study was progression-free survival PFS. Secondary objectives included objective response rate, or ORR, duration of response, and overall survival, or OS. A key pre-defined exploratory population was those patients who had high levels of circulating DKK1, as measured by a biomarker assay. Key Part B DeFianCe Study Findings includes: Across the DKK1-high patients: ORR was 38.0% in the Sirexatamab Arm compared to 23.7% ORR in the Control Arm; mPFS was 9.03 months in the Sirexatamab Arm compared to 7.06 months in the Control Arm, Hazard Ratio 0.61, p-value = 0.0255; mOS was not reached in the Sirexatamab Arm compared to 14.39 months in the Control Arm, HR 0.42, p-value = 0.0118; Across the DKK1-high patients: ORR was 44.0% in the Sirexatamab Arm compared to 15.8% ORR in the Control Arm.

Leap Therapeutics reports updated results from Phase B of DeFianCe study

Leap Therapeutics reported updated results from Part B of the DeFianCe study, a Phase 2 study of sirexatamab, DKN-01, an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy compared to bevacizumab and chemotherapy in patients with advanced microsatellite stable, MSS, colorectal cancer, CRC, who have received one prior systemic therapy for advanced disease. Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naive and liver metastasis subgroups. "Sirexatamab demonstrated a statistically significant benefit in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, with a positive trend on ORR and PFS in the full second-line CRC population. With the additional patient follow-up, we believe that the objectives of the DeFianCe study have been achieved," said Douglas E. Onsi, President and Chief Executive Officer of Leap.